8-K: LENZ Therapeutics Reports Strong Q4 2025 VIZZ Launch

LENZ Therapeutics announced preliminary unaudited Q4 2025 financial results, reporting $1.6 million in VIZZ net product revenue and over 20,000 prescriptions filled.

Summary

• Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability by mid-November 2025.
• Achieved approximately $1.6 million in net product revenue and over 20,000 prescriptions filled for VIZZ in Q4 2025.
• Over 6,500 unique Eye Care Professionals (ECPs) prescribed VIZZ, with more than 55% prescribing multiple times in Q4 2025.
• Announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East in January 2026, marking the fourth international partnership.
• VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, a condition affecting an estimated 1.8 billion people globally and 128 million in the United States.
• The most common reported adverse reactions were instillation site irritation (20%), dim vision (16%), and headache (13%).

Sentiment

Score: 8

Explanation: The filing reports strong initial commercial success for VIZZ, exceeding management's expectations for prescriptions and establishing significant ECP adoption in its first quarter. The international partnership further enhances future growth prospects.

Positives

• Strong initial commercial execution for VIZZ, exceeding expectations with over 20,000 prescriptions filled in its first quarter of launch.
• Achieved approximately $1.6 million in net product revenue in Q4 2025, demonstrating early market traction.
• Rapid uptake by Eye Care Professionals (ECPs), with over 6,500 unique prescribers and more than 55% prescribing multiple times, signaling early confidence.
• Secured an exclusive commercialization partnership with Lunatus in the Middle East, expanding VIZZ's global reach and revenue potential.
• VIZZ is positioned as the first and only aceclidine-based eye drop for presbyopia, offering a unique treatment option in a large market.
• Upcoming launch of a Direct-to-Consumer (DTC) campaign with Sarah Jessica Parker is expected to further drive awareness and adoption.

Negatives

• The reported financial results for Q4 2025 are preliminary and unaudited, subject to completion of accounting and annual audit procedures and potential adjustment.
• Common adverse reactions include instillation site irritation (20%), dim vision (16%), and headache (13%).

Risks

• Forward-looking statements are subject to substantial risks, uncertainties, and other factors that may cause actual results to differ materially from expectations.
• Preliminary unaudited financial results are subject to adjustment upon completion of the company's accounting and annual audit procedures.
• Temporary dim or dark vision may be experienced after using VIZZ, which could impair the ability to drive or operate machinery.
• Risk of potential eye injury or product contamination if the vial tip touches the eye or other surfaces during use.

Future Outlook

The company anticipates launching its VIZZ Direct-to-Consumer (DTC) campaign with spokesperson Sarah Jessica Parker during the current quarter (Q1 2026). LENZ Therapeutics also plans to continue establishing international licensing partnerships to expand global access to VIZZ.

Management Comments

• "We are proud of the strong execution delivered in our first quarter of launch, as the team established a solid foundation of awareness, confidence, and willingness to prescribe VIZZ across the eye care professional community."
• "More than 6,500 eye care professionals have already written a prescription for VIZZ, the majority of whom prescribed multiple times, signaling early confidence in VIZZ as a convenient and effective alternative to reading glasses."
• "At the same time, over 20,000 prescriptions were filled during our first quarter of launch, exceeding our expectations and reinforcing the early momentum behind VIZZ."
• "Building on this progress, and together with our campaign spokesperson Sarah Jessica Parker, we look forward to launching the VIZZ DTC campaign this quarter."

Industry Context

Presbyopia is a highly prevalent age-related vision condition, impacting an estimated 1.8 billion people globally and 128 million in the United States, typically managed with reading glasses or other corrective aids. VIZZ enters this large market as the first and only aceclidine-based prescription eye drop, offering a novel treatment alternative. The company's strategy of securing international commercialization partnerships indicates a strong focus on capturing global market share beyond the U.S.

Stakeholder Impact

• Shareholders: Positive impact due to strong initial product launch performance, exceeding expectations, and strategic international expansion, potentially leading to increased revenue and market share.
• Patients (Presbyopia sufferers): VIZZ offers a new, convenient, and effective prescription eye drop alternative to traditional corrective aids.
• Eye Care Professionals (ECPs): High adoption rate and repeat prescribing indicate confidence in VIZZ as a viable treatment option.
• Employees: Positive outlook due to successful product launch and company growth, potentially leading to job security and opportunities.
• Partners (Lunatus): The new commercialization partnership provides revenue share and market access in the Middle East, benefiting the partner.

Next Steps

• Launch the VIZZ Direct-to-Consumer (DTC) campaign with Sarah Jessica Parker in Q1 2026.
• Continue to establish international licensing partnerships for VIZZ to expand global access.
• Complete accounting and annual audit procedures for the preliminary unaudited Q4 2025 financial results.

Key Dates

Recommendation

The initial launch of VIZZ has significantly exceeded expectations, demonstrating strong market acceptance and rapid uptake by eye care professionals. The reported $1.6 million in net product revenue and over 20,000 prescriptions filled in the first quarter are impressive for a new product. The strategic international partnership with Lunatus further expands the market opportunity. While preliminary, these results indicate robust commercial execution and strong potential for future growth in a large, underserved market. The upcoming DTC campaign is likely to further accelerate adoption, making this a compelling investment opportunity.

Keywords

LENZ Therapeutics, VIZZ, aceclidine, presbyopia, eye drops, ophthalmic solution, pharmaceutical, Q4 2025, financial results, product launch, commercialization, eye care, FDA approved, near vision